Physician

Joseph E Temming, MD

According to 2025 Medicare claims, Joseph Temming, MD (NPI: 1407851215) practices rheumatology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Boone, KY. This provider's primary affiliated billing organization is TRISTATE ARTHRITIS & RHEUMATOLOGY PSC (NPI: 1851449425; TIN: 611104130) and primary practice location at 41017-2418. Temming is affiliated with the Healthcare Solutions Network (ACO ID: A3283), participating under the MSSP model.

Temming's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 211 traditional Medicare patients, billed 106,534 HCPCS/CPT codes, and received $1,338,921 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,523 prescription claims across 227 beneficiaries totaling $376,486 in drug costs, led by Enbrel Sureclick (Etanercept). 2015 DME data shows 14 claims. Open Payments data shows 10 records totaling $285. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $772,399 to $1,338,921. In contrast, Part D prescription costs have declined steadily, from $529,954 to $376,486. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	405	33,501	$772,399
2016	440	54,758	$996,072
2017	410	49,784	$1,041,126
2018	469	50,281	$1,176,213
2019	454	55,248	$1,263,397
2020	336	62,686	$1,515,350
2021	321	73,913	$1,534,721
2022	262	93,291	$1,406,168
2023	240	79,759	$1,284,307
2024	211	106,534	$1,338,921

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	360	2,532	$529,954
2016	365	2,646	$486,192
2017	372	2,907	$516,312
2018	399	3,027	$607,255
2019	428	3,084	$655,125
2020	369	2,611	$422,127
2021	348	2,304	$385,995
2022	290	1,878	$363,758
2023	255	1,634	$418,744
2024	227	1,523	$376,486

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	14	$1,766
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	177	367	$89
96413	Administration of chemotherapy into vein, 1 hour or less	48	435	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	74	109	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	180	358	$12
J1010	Injection, methylprednisolone acetate, 1 mg	56	8,340	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	34	952	$238,410
Methotrexate	Methotrexate Sodium	291	19,292	$5,470
Mycophenolate Mofetil	Mycophenolate Mofetil	25	1,050	$3,260
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	88	6,435	$2,599
Tramadol Hcl	Tramadol Hcl	265	7,762	$1,695

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$285	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Joseph E. Temming, MD?

Tedicare shows public-source Medicare data for Joseph E. Temming, MD (NPI 1407851215), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joseph E. Temming, MD have ACO affiliation data?

Joseph E. Temming, MD is shown with ACO affiliation data for Healthcare Solutions Network (MSSP, ACO ID A3283).

What billing organization is linked to Joseph E. Temming, MD?

Joseph E. Temming, MD is linked to TRISTATE ARTHRITIS & RHEUMATOLOGY PSC (billing NPI 1851449425) in the available physician profile data.

Does Joseph E. Temming, MD have Open Payments data?

Joseph E. Temming, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.